 Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void? 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
